Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Trial Details

NCT ID

NCT04900818

Phase

PHASE1

Sponsor

I-Mab Biopharma US Limited

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

• TJ033721 (givastomig)
• TJ033721 (givastomig) , nivolumab, chemotherapy
• TJ033721 (givastomig), chemotherapy
• TJ033721 (givastomig), durvalumab, chemotherapy

Locations (sample)

• Orange, California, United States|33.78779,-117.85311
• Aurora, Colorado, United States|39.72943,-104.83192
• Layfayette, Indiana, United States
• Boston, Massachusetts, United States|42.35843,-71.05977
• New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

• Part 1 - Monotherapy Subjects with advanced or metastatic solid tumor in subjects whose disease has progressed despite standard therapy, or who has…
• Part 2 - Combination Therapy Subjects with treatment naïve locally advanced, unresectable or metastatic gastric, GEJ, esophageal adenocarcinoma;
• Part 3: Combination Therapy Subjects with unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma;
• Part 4: Combination Therapy Subjects with unresectable, locally advanced or metastatic histologically confirmed biliary tract cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.